Oral cyclic peptides · Companies

D

Debiopharm

Compare

Alisporivir (Debio 025) is a cyclosporine-derived cyclophilin inhibitor with historical clinical development. A 2021 trial does not establish current active status.

X

XtalPi

Compare

PepiX™ connects AI, automated synthesis, and experimental screening. The website identifies oral cyclic peptides as a priority; food-peptide GRAS status is not pharmaceutical evidence.

H

HitGen

Compare

The company's interim report describes peptidomimetic macrocycle discovery, optimization, and oral applications. DEL and platform capabilities do not establish human oral evidence for proprietary candidates.

I

IRBM

Compare

Provides optimization of macrocyclic peptides derived from mRNA / phage display. Its website reports involvement in developing Merck's oral PCSK9 peptide MK-0616.

CT

Curve Therapeutics

Compare

Microcycle® functionally screens compact macrocycles in live cells and develops macrocycle-derived drugs. This review did not confirm a named oral cyclic peptide candidate.

Its peptide screening platform covers linear, cyclic, and helical structures, so it is included as an adjacent discovery capability. It is not automatically classified as a validated oral cyclic peptide drug developer.

A

Asymchem

Compare

An original October 2026 investor record identifies oral cyclic peptides as a priority business and states that orders have been received. Only manufacturing services are recorded; proprietary drug pipelines are not inferred.

H

Henlius

Compare

Original company materials confirm cyclic peptides as a development modality. This review did not find a primary announcement sufficient to verify a specific oral candidate and its current stage.

SG

Sunshine Guojian

Compare

An investor record describes program 629 as an oral IL-23 cyclic peptide with PK suggesting once-weekly potential. Human results and the latest stage were not confirmed in this review.

SB

Sciwind Biosciences

Compare

The OralVantage™ oral peptide platform combines molecular stabilization and formulation strategies. It is included as a noncyclic peptide platform reference; validated oral cyclic peptides are not assumed.

Founded in 2026, this early-stage oral long-acting peptide company describes molecular design, microbial expression, and OMV packaging / delivery. Cyclic peptide identity and human evidence require verification.

BT

Bicycle Therapeutics

Compare

An important adjacent company in bicyclic peptide screening and conjugation. Its disclosed nonoral clinical pipeline is not evidence of oral cyclic peptide success.

H→

Hepion → Panetta Partners

Compare

Rencofilstat (CRV431) has oral clinical studies in MASH. Hepion transferred related assets to Panetta in 2025; the record preserves the historical development and change in rights.

ST

Sublimity Therapeutics / Sigmoid heritage

Compare

ST-0529 is an oral cyclosporine formulation for UC with historical Phase 2 registration. The Romanian record reviewed is marked prematurely ended. Current ownership and company status require verification.

SP

Sorriso Pharmaceuticals

Compare

SOR102 is a locally acting oral TNF / IL-23 bispecific single-domain antibody with a primary Phase 1 study. It is included as a noncyclic oral biologic reference.

DF

Dr. Falk Pharma

Compare

The ST-0529 oral cyclosporine Phase 2 registry lists the company as a study supporter. That regional record ended prematurely; current development rights or collaboration budgets are not inferred.

B

Bachem

Compare

Provides process development, analytical services, and GMP clinical manufacturing for cyclic peptides, stapled peptides, and peptidomimetics. Classified as a manufacturing service provider; client drugs are not treated as proprietary pipelines.

WA

WuXi AppTec / WuXi TIDES

Compare

The website describes a client case for a non-GLP-1 oral cyclic peptide, from library synthesis and lead optimization through GMP preparation. Only service capability is recorded; the unnamed client is neither identified nor guessed.

PP

Porton Pharma

Compare

The TIDES platform covers process development, analytics, and manufacturing for monocyclic, polycyclic, and modified peptides. This review did not confirm a named oral cyclic peptide program.

A

Almac

Compare

Original technical materials describe macrocycle, stapled peptide, and bicyclic peptide synthesis. Included as discovery / manufacturing services, not elevated to an oral clinical drug developer.

B/

Biosynth / Pepscan

Compare

CLIPS™ supports monocyclic, bicyclic, and tricyclic constrained peptides, screening, and optimization. Recorded at the integrated-group level; oral suitability requires program-level validation.

A

AmbioPharm

Compare

The company describes constrained peptide chemistry involving disulfides, lactam bridges, stapling, and other cyclization approaches. This review did not confirm a proprietary oral cyclic peptide candidate.

MA

Menten AI

Compare

MAUD 1.0 combines generative AI, physics-based modeling, and quantum simulations to design cyclic peptides. The company explicitly optimizes oral bioavailability and cell permeability and works with pharmaceutical partners on discovery.

PP

Processa Pharmaceuticals

Compare

An October 2026 research collaboration and exclusive option agreement with Generian advances an oral macrocyclic peptide FcRn antagonist. This research-stage program is separate from Processa’s Phase 2 small-molecule BTK inhibitor VT-7208.